Dupilumab
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Eczema
Conditions
Eczema, Atopic Dermatitis
Trial Timeline
Mar 1, 2022 → Mar 1, 2024
NCT ID
NCT05265234About Dupilumab
Dupilumab is a approved stage product being developed by Regeneron Pharmaceuticals for Eczema. The current trial status is unknown. This product is registered under clinical trial identifier NCT05265234. Target conditions include Eczema, Atopic Dermatitis.
What happened to similar drugs?
1 of 12 similar drugs in Eczema were approved
Approved (1) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
20 competing products in Eczema